A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors.

Wang-Gillam A, Tew WP, Rothenberg ML, Dupont J, Cooper W, Sternas L, Buzenet G, Sosman JA, Spriggs DR, Lockhart AC
Invest New Drugs. 2012 30 (5): 1958-61

PMID: 22002018 · PMCID: PMC3432791 · DOI:10.1007/s10637-011-9753-y

MeSH Terms (15)

Adult Aged Angiogenesis Inhibitors Antineoplastic Agents Chemistry, Pharmaceutical Cohort Studies Female Humans Male Middle Aged Neoplasms Neovascularization, Pathologic Receptors, Vascular Endothelial Growth Factor Recombinant Fusion Proteins Vascular Endothelial Growth Factor A

Connections (1)

This publication is referenced by other Labnodes entities: